PDCD1 and neoplasm: Finally, BRCA1/2-mutated OCs also exhibited a significantly increased expression of immune checkpoint modulators, such as PD-1 and PD-L1, suggesting an interplay between HR status, the immune microenvironment within the tumor, and the clinical outcome of HGOC patients [108].